Rectal cancer surgery has many important technical considerations, including the significant challenges of operating within a confined space with limited visibility and maneuverability. These problems are accentuated in patients with an elevated body mass index, android pelvis, bulky tumor, enlarged prostate, and fibrosis following neoadjuvant chemoradiotherapy. The general consensus is that such obstacles may potentially compromise oncologic adequacy by resulting in incomplete total mesorectal excision (TME) and/or positive resection margins.
criticized for non-validated data entry, the international taTME registry corroborated these favorable preliminary oncologic outcomes [9] , even though, in aggregate, longterm oncologic results were lacking.
Despite the rapid globalization of taTME, adoption has been tempered by caution given the complexity of the procedure including a long learning curve, and the concerning reports detailing procedure-specific morbidity. These complications have included CO 2 embolus, male urethral injury, and potential contamination secondary to purse string failure. Anastomotic leak rates, which were initially believed to be lower with taTME than with abdominal approaches, have been shown to be higher in the Dutch and International taTME registries, vis-à-vis leak rates reported in the COLOR II and CLASSIC trials. Perhaps due to the aforementioned reports, a taTME trial originating from Sahlgrenska University Hospital in Sweden and registered on clinicaltrials.gov has been suspended. Most concerning, in Norway, a widely publicized moratorium on taTME has been issued, substantiated by reports of higher than expected local recurrence rates.
The Norwegian report by Larsen et al. [10] describes a 9.5% local recurrence rate at a median follow-up of 11 months among 110 patients who had taTME for rectal cancer over a 3-year period at (mainly) four hospitals. This rate-well in excess of the 3.4% rate of local recurrence from the Norwegian Colorectal Cancer Registry, and double the rate observed in COLOR II [11] -has prompted the nationwide cessation of taTME. In Norway, local failure data are likely to be accurately captured, because all local recurrences are referred to a single center-the Norwegian Radium Hospital in Oslo. Assuming that taTME cases were evenly distributed among the four participating hospitals over a 3-year period, the per center experience would equate to nine taTME cases per year which may not qualify as "high volume". Moreover, the pre-taTME experience of these surgeons with both laparoscopic TME and transanal endoscopic surgery was not stipulated; mastery of these skills is an important prerequisite to embarking upon taTME.
While many case specifics are yet to be analyzed-including the use of neoadjuvant therapy, intraoperative complications such as perforation and purse string disruption, and postoperative morbidity such as anastomotic leaks and pelvic abscess-the article deserves attention. These cases of local recurrence which occurred early and with multifocal pelvic side wall involvement are atypical for local failure after traditional TME. Larsen et al. hypothesized that this phenomenon may be the direct consequence of transanal purse string failure. At least in theory, exfoliated tumor cells can either directly seed the resection bed or become aerosolized during taTME dissection. Despite the lack of scientific evidence to substantiate this hypothesis, the specter of technical inadequacy highlights the need for standardized education, training, and proctoring. To date, the Norway report stands in sharp contrast with all prior reports and observations on short-term oncologic outcomes of taTME. Notwithstanding, it has intensified the need for 3-and 5-year long-term oncologic outcomes of the procedure that was first described in 2009 [12] .
In this issue of Techniques in Coloproctology, Hol et al. (Netherlands) are the first group to report on their 3-to 5-year oncologic outcomes in one of the largest cohorts of patients who had taTME [13] . The study is perfectly timed, in immediate succession to the Norway moratorium. In this consecutive series of 159 patients, the 3-and 5-year local recurrence rates were 2% and 4%, respectively, a local failure rate comparable to the 5% loco-regional recurrence rate observed in the COLOR II trial (for both open and laparoscopic TME) [11] . Furthermore, Hol et al. reported the disease-free survival rate at 5 years to be 81%, an acceptable long-term outcome for locally advanced rectal cancer.
The discordance in oncologic outcomes between Norway and the Netherlands needs to be analyzed. Could this have been related to the fact that all taTME cases were centralized to a single center in the Netherlands, while results were pooled among four centers (or possibly more) in Norway? Are there factors specific to the implementation of taTME programs that could so drastically affect patient outcomes? The answers to these questions are difficult to elucidate since the Norway moratorium (reported as a lead article in The British Journal of Surgery), did not disclose pertinent case specifics. Thus, there is a dearth of data from which to draw any meaningful conclusions, leaving readers with more questions than answers. A plausible rationale could be variations in surgeon expertise and center volume. One clue suggesting the validity of this supposition is that local recurrence (but not distant failure) has been found to be significantly higher in low-volume taTME centers when compared to high-volume centers (8.9% vs 2.8%) [14] . It is conceivable that the technical quality of taTME dissection could impact oncologic outcome, and yet this critical variable cannot be measured by interpreting specimen quality and the often referenced surrogate markers of oncologic adequacy. Larsen et al. quite astutely state in their report, "local recurrences related to the rectal transection and air flow during dissection from the perineum cannot be evaluated by examining the specimen" [10] .
While training pedagogies for taTME in Europe and North America have been remarkably well conceived and orchestrated [15, 16] , there remain some deficits. The overtraining of surgeons who lack case volume is one example. In the United States more than 400 surgeons have received taTME training in preparation for implementing the operation; perhaps only 25 of whom could be considered "highvolume" rectal cancer surgeons. Thus, many surgeons may never gain a sufficient level of technical competency due to lack of volume. Another limitation of current taTME training paradigms is that there is a lack of structured proctoring and mentorship to assure successful implementation. Because of the complexity of the operation, most surgeons experienced with taTME concur that formalized proctoring should be an integral component along the training pathway, and that there is value in educating a dedicated OR team so that case flow and choreography are optimized.
An important parallel can be drawn from the early 1990s-when Berends et al. noted a 21% incidence of port site recurrence [17] -to today, when Norwegians have reported a prohibitively high local recurrence rate with taTME. The response to Berends' report included national moratoria on the performance of laparoscopic colorectal surgery for malignancy. In addition, the single report from Berends et al. and a few other case reports were of sufficient concern to prompt societies to create guidelines about the learning, implementation, and subsequent use of laparoscopic colorectal surgery. In the United States, the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and the American Society of Colon and Rectal Surgeons (ASCRS) created a task force which presented and published a training schema [18] . In the United Kingdom, The National Training Program in Laparoscopic Colorectal Surgery (LAPCO) was developed to ensure appropriate training prior to performance of laparoscopic colorectal surgery. The implementation of taTME should be adopted under a similar framework. Ultimately, the outlier publications in which unacceptably high incidence of port site recurrences were reported, faded into the annals of surgical history as they were proven by time, trials, and data to be aberrations.
The next decade will likely show a continued use of taTME, although it should probably be used more selectively with more stringent selection criteria. All patients with rectal cancer should receive care from teams who specialize in and ideally perform high volumes of rectal cancer care. In the USA, these centers should ideally all become accredited by the American College of Surgeons Commission on 1 3
Cancer National Accreditation Program for Rectal Cancer [19] . Training should be remodeled-with an emphasis on formal proctoring [20] . Ultimately, taTME should be maintained as a valid solution to the specific challenge of low pelvic dissection. In the near future, taTME collaborative studies including COLOR III and the North American Multicenter Phase II Study on Transanal TME are expected to clarify the expected norms for oncological outcomes on a more global scale. We believe that the adverse outcomes reported in Norway are avoidable by stringent patient selection, structured surgical training, and frequent performance of taTME within the context of high-volume specialty teams. We are optimistic that these potentially avoidable aberrant results will be relegated into the footnotes of future commentaries alongside the results of Berends et al., and that taTME will, in fact, stand the test of time.
Compliance with ethical standards
Conflict of interest Dr. Sam Atallah reports consultancy for Applied Medical, Inc., ConMed, Inc., Medtronic, and Auris Health. Dr. Steven Wexner reports consulting fees and royalties for intellectual property license from Intuitive Surgical, Medtronic, and Karl Storz, as well was consulting fees for Tigenix. Dr. Patricia Sylla reports grant support for the Phase II North American taTME Trial from Ethicon, Inc., Medtronic, Karl Storz, Stryker, Novadaq, Richard Wolf, Olympus, and Applied Medical, Inc.
Ethical approval This article does not contain any study of human participants or animals performed by any of the authors.
Informed consent For this article formal consent in not applicable.
